Karl Handelsman is the founder and general partner of Codon Capital. He has also served as a senior advisor to the Roche Venture Fund and as a member of the board of directors of Good Therapeutics. From May 2013 to April 2014, he served as General Partner Emeritus at CMEA Capital. He is also a member of the board of directors of Bonum Therapeutics. In May 2013, he stepped back from active involvement with CMEA Capital. He has been involved in numerous CMEA investments such as Ambrx, Ensemble Discovery, Ilypsa, Intellikine, Kalypsys, Maxygen, Phenomix, Rigel, Syrrx, Tetraphase and Xenoport. He was a member of the board of directors of Ensemble Therapeutics. Prior to joining CMEA, he was an early employee of Tularik, a drug development company, where he was involved in business development, including corporate partnerships, technology licensing and operations. He was also an early employee of the Whitehead Institute, a leading research organization at MIT, and worked in business development at Millennium Pharmaceuticals. He is a graduate of MIT and Harvard Medical School.